Association of Pre-End-Stage Renal Disease Hemoglobin with Early Dialysis Outcomes

American Journal of Nephrology

Volumn 47, Issue 5, 2018, Pages 333-342

  Kleine, Carola Ellen ^a,b   Soohoo, Melissa ^a,b,c   Ranasinghe, Omesh N ^a   Park, Christina ^a,b   Marroquin, Maria V ^a,b   Obi, Yoshitsugu ^a   Rhee, Connie M ^a   Moradi, Hamid ^a,b   Kovesdy, Csaba P ^d,e   Kalantar Zadeh, Kamyar ^a,b,c   Streja, Elani ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anemia; Chronic kidney disease; End stage renal disease; Hemoglobin; Mortality

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; FERRITIN; HEMOGLOBIN;

AGED; ALL CAUSE MORTALITY; ARTICLE; BICARBONATE BLOOD LEVEL; BODY MASS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULONEPHRITIS; HEART INFARCTION; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY POLYCYSTIC DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE EXACERBATION; INCIDENCE; MIDDLE AGED; MORTALITY; PROCEDURES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; VETERAN;

AGED; ANEMIA; DISEASE PROGRESSION; FEMALE; HEMOGLOBINS; HOSPITALIZATION; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; VETERANS;

EID: 85047424011     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000489223     Document Type: Article

References (39)

1. Babitt JL, Lin HY: Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23: 1631-1634.
2. Schmidt RJ, Dalton CL: Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopath Med Prim Care 2007; 1: 14.
3. Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH: Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton) 2009; 14: 240-246.
4. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M: The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501-1510.
5. KDIGO clinical practice guideline for anemia and chronic kidney disease. Kidney International Supplements 2012; 2: 283-287. http:// www. kdigo. org/clinical-practice-guidelines/ pdf/KDIGO-Anemia%20GL. pdf.
6. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185.
7. Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Mombelloni S, Visioli O, Maiorca R: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 1991; 6: 31-37.
8. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-256.
9. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548.
10. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990; 300: 573-578.
11. Kimel M, Leidy NK, Mannix S, Dixon J: Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value Health 2008; 11: 57-75.
12. Fink J, Blahut S, Reddy M, Light P: Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001; 37: 348-355.
13. Kataoka H, Tsuchiya K, Naganuma T, Okazaki M, Komatsu M, Kimura T, Shiohira S, Kawaguchi H, Nitta K: Relationship between anaemia management at haemodialysis initiation and patient prognosis. Nephrology (Carlton) 2015; 20(suppl 4): 14-21.
14. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 2007; 369: 381-388.
15. Singh AK: The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol 2010; 5: 553-556.
16. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesis-stimulating agents-time for a reevaluation. N Engl J Med 2010; 362: 189-192.
17. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191.
18. Kalantar-Zadeh K, Kovesdy CP, Streja E, Rhee CM, Soohoo M, Chen JLT, Molnar MZ, Obi Y, Gillen D, Nguyen DV, Norris KC, Sim JJ, Jacobsen SS: Transition of care from pre-dialysis prelude to renal replacement therapy: The blueprints of emerging research in advanced chronic kidney disease. Nephrol Dial Transplant 2017; 32(suppl 2):ii91-ii98.
19. Molnar MZ, Gosmanova EO, Sumida K, Potukuchi PK, Lu JL, Jing J, Ravel VA, Soohoo M, Rhee CM, Streja E, Kalantar-Zadeh K, Kovesdy CP: Predialysis cardiovascular disease medication adherence and mortality after transition to dialysis. Am J Kidney Dis 2016; 68: 609-618.
20. Sumida K, Diskin CD, Molnar MZ, Potukuchi PK, Thomas F, Lu JL, Rhee CM, Streja E, Yamagata K, Kalantar-Zadeh K, Kovesdy CP: Pre-end-stage renal disease hemoglobin variability predicts post-end-stage renal disease mortality in patients transitioning to dialysis. Am J Nephrol 2017; 46: 397-407.
21. Sumida K, Molnar MZ, Potukuchi PK, Thomas F, Lu JL, Jing J, Ravel VA, Soohoo M, Rhee CM, Streja E, Kalantar-Zadeh K, Kovesdy CP: Association of slopes of estimated glomerular filtration rate with post-end-stage renal disease mortality in patients with advanced chronic kidney disease transitioning to dialysis. Mayo Clin Proc 2016; 91: 196-207.
22. US renal Data System: USRDS 2017 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States, Chapter 8: Transition of Care in Chronic Kidney Disease. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2017.
23. Obi Y, Park C, Soohoo M, Sumida K, Hamano T, Rhee CM, Kovesdy CP, Kalantar-Zadeh K, Streja E: Association of pre-ESRD serum calcium with post-ESRD mortality among incident ESRD patients: A cohort study. J Bone Miner Res 2018, Epub ahead of print.
24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
25. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.
26. Besarab A, Soman S: Anemia management in chronic heart failure: lessons learnt from chronic kidney disease. Kidney Blood Press Res 2005; 28: 363-371.
27. Eckardt KU: Managing a fateful alliance: Anaemia and cardiovascular outcomes. Nephrol Dial Transplant 2005; 20(suppl 6): vi16-vi20.
28. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
29. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
30. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
31. Lukowsky LR, Kheifets L, Arah OA, Nissenson AR, Kalantar-Zadeh K: Patterns and predictors of early mortality in incident hemodialysis patients: new insights. Am J Nephrol 2012; 35: 548-558.
32. Robinson BM, Zhang J, Morgenstern H, Bradbury BD, Ng LJ, McCullough KP, Gillespie BW, Hakim R, Rayner H, Fort J, Akizawa T, Tentori F, Pisoni RL: Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int 2014; 85: 158-165.
33. Thein SL, Menzel S: Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 2009; 145: 455-467.
34. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773.
35. Priyadarshi A, Shapiro JI: Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Semin Dial 2006; 19: 273-278.
36. Ebben JP, Gilbertson DT, Foley RN, Collins AJ: Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006; 1: 1205-1210.
37. Ogawa T, Nitta K: Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients. Contrib Nephrol 2015; 185: 76-86.
38. Fishbane S, Besarab A: Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2: 1274-1282.
39. Jeong SK, Cho YI, Duey M, Rosenson RS: Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment Cardiovasc Drugs Ther 2010; 24: 151-160.